Richard S. Finn, MD
Second-line regorafenib (Stivarga) continued to show antitumor activity regardless of prior dose or time to progression (TTP) on frontline sorafenib (Nexavar) for patients with unresectable advanced hepatocellular carcinoma (HCC), according to additional analyses from the phase III RESORCE trial published in the Journal of Hepatology
Regorafenib was approved by the FDA in April 2017 for the treatment patients with hepatocellular carcinoma (HCC) who have previously received sorafenib, based on findings from the RESORCE trial. The agent is also approved for the treatment of patients with metastatic colorectal cancer and advanced gastrointestinal stromal tumors.
- Finn RS, Merle P, Granito A, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase 3 RESORCE trial [published online April 25, 2018]. J Hepatol. 2018.
- Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56-66.
... to read the full story